TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15331798

Group type: EXPERIMENTAL
Intervention: Pexelizumab (bolus and infusion)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Pexelizumab (bolus plus infusion)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study: 11410193

Group type: EXPERIMENTAL
Intervention: infliximab 5 mg/kg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: infliximab 10 mg/kg
Number of subjects: 33

Group type: COMPARATOR
Intervention: intravenous placebo
Number of subjects: 33
Study: 9243353

Group type: EXPERIMENTAL
Intervention: Desmethylselegiline (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Selegiline (10 mg)
Number of subjects: 10
Study: 7684219

Group type: EXPERIMENTAL
Intervention: 30,000 KIU/kg aprotinin in the CPB priming volume and 7,500 KIU/kg aprotinin intravenously each hour during CPB
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 27
Study: 3610893

Group type: EXPERIMENTAL
Intervention: Behavioral practice, assertiveness training, and social and contrived reinforcers (Group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Behavioral practice, assertiveness training, and social and contrived reinforcers (Group 2)
Number of subjects: 16
Study: 31755599

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the STN combined with best medical treatment
Number of subjects: 251

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 251
Study: 31150791

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1897

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1897
Study: 28327086

Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention using a web tool
Number of subjects: 21
Study: 25595527

Group type: EXPERIMENTAL
Intervention: Invasive treatment (coronary angiography performed) - 182 patients
Number of subjects: 313

Group type: COMPARATOR
Intervention: Conservative treatment (no coronary angiography) - 131 patients
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 313
Study: 23949975

Group type: EXPERIMENTAL
Intervention: Preventive home visits by nurses or care managers every 6 months over 2 years
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 323
Study: 21367726

Group type: EXPERIMENTAL
Intervention: 23vP administered after priming with 2 doses of PCV7
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Single dose of PCV7
Number of subjects: 348

Group type: COMPARATOR
Intervention: 23vP
Number of subjects: 348
Study: 19241799

Group type: EXPERIMENTAL
Intervention: Dry-needling
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.25% Lidocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 45
Study: 16754728

Group type: COMPARATOR
Intervention: Tamoxifen (n = 973)
Number of subjects: 19747

Group type: EXPERIMENTAL
Intervention: Raloxifene (n = 1010)
Number of subjects: 19747
Study: 15449741

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC concentration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TIVA Propofol (6 mg/kg/h infusion)
Number of subjects: 40
Study: 11445795

Group type: EXPERIMENTAL
Intervention: Behavioral, family-based treatment
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Parental involvement in treatment
Number of subjects: 47
Study: 9767362

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (15 mg per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 24
Study: 7936334

Group type: EXPERIMENTAL
Intervention: FTTCA (Centella asiatica) 30 mg bid
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: FTTCA (Centella asiatica) 60 mg bid
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 3068300

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d.)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 29999572

Group type: EXPERIMENTAL
Intervention: Aprepitant-containing regimen
Number of subjects: 0
Study: 26381165

Group type: COMPARATOR
Intervention: 80 mg simvastatin alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 mg piragliatin alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin and 100 mg piragliatin together
Number of subjects: 30
Study: 24452825

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy with adjunctive systemic amoxicillin and metronidazole (n=19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (both groups)
Number of subjects: 40
Study: 22673159

Group type: EXPERIMENTAL
Intervention: Video-assisted debriefing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral debriefing alone
Number of subjects: 30
Study: 20829150

Group type: EXPERIMENTAL
Intervention: Modified triangular flap
Number of subjects: 17

Group type: COMPARATOR
Intervention: Buccal envelope flap (control)
Number of subjects: 17
Study: 18164452

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for chronic low back pain; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical interventions for chronic low back pain; specific interventions not detailed.
Number of subjects: 0
Study: 15880022

Group type: EXPERIMENTAL
Intervention: Everolimus (Certican) in combination with reduced-exposure cyclosporine (CsA)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Everolimus (Certican)
Number of subjects: 2
Study: 12598264

Group type: COMPARATOR
Intervention: Morphine plus saline (MS; n = 114)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Morphine plus ketamine (MK; n = 131)
Number of subjects: 245
Study: 10367600

Group type: EXPERIMENTAL
Intervention: Perindopril (PER), 2 mg once daily
Number of subjects: 725

Group type: COMPARATOR
Intervention: Captopril (CAP), 6.25 mg t.i.d.
Number of subjects: 725

Group type: COMPARATOR
Intervention: Captopril (CAP)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Perindopril (PER)
Number of subjects: 725
Study: 8665256

Group type: EXPERIMENTAL
Intervention: Laparoscopic posterior truncal vagotomy (PTV) and anterior linear gastrectomy (ALG)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Laparoscopic PTV with ALG
Number of subjects: 136
Study: 1855277

Group type: EXPERIMENTAL
Intervention: 200 mg prednimustine
Number of subjects: 12
Study: 6869546

Group type: EXPERIMENTAL
Intervention: Meal A (baked beans and polyethylene glycol (PEG 4000))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Meals B and C (unassociated with generation of breath hydrogen)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All meals (A, B, and C)
Number of subjects: 6
Study: 31933341

Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DY)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Static stretching (ST)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Static + dynamic stretching (ST+DY)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dynamic + static stretching (DY+ST)
Number of subjects: 11
Study: 29389835

Group type: EXPERIMENTAL
Intervention: 4 mg (oral) SAL
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 800 μg (inhaled) SAL
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 27888180

Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Resources for Enhancing Alzheimer's Caregivers Health (REACH)
Number of subjects: 200
Study: 25412911

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 3169

Group type: EXPERIMENTAL
Intervention: Watchful Waiting (WW)
Number of subjects: 3169

Group type: COMPARATOR
Intervention: Hormonal treatment, Radiotherapy, Operation
Number of subjects: 3169
Study: 22659156

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cognitive defusion (across both CBT and ACT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity (across both CBT and ACT)
Number of subjects: 67
Study: 20042444

Group type: EXPERIMENTAL
Intervention: 0.3 microg/kg DDAVP
Number of subjects: 22

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 22
Study: 17510908

Group type: EXPERIMENTAL
Intervention: Training newborn hearing screeners to present information about the screening test and to ask questions to check understanding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Questionnaires sent to screeners to elicit their responses
Number of subjects: 30
Study: 16055642

Group type: EXPERIMENTAL
Intervention: Context prime of opposite valence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Context prime of same valence
Number of subjects: 0
Study: 12810176

Group type: EXPERIMENTAL
Intervention: Oral ibandronate 20 mg weekly for 84 days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral ibandronate 2.5 mg daily for 84 days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cumulative dose 130 mg or less
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Serial measurements of s-CTX
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment for 168 days
Number of subjects: 200
Study: 10589647

Group type: EXPERIMENTAL
Intervention: IV amino acid mixture, 126 mL/h
Number of subjects: 45

Group type: COMPARATOR
Intervention: Acetated Ringer's solution
Number of subjects: 45
Study: 8616532

Group type: EXPERIMENTAL
Intervention: Thiamazole 20mg/day for 14 days
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sodium perchlorate 900mg/day for 14 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study: 1817629

Group type: EXPERIMENTAL
Intervention: Diamorphine 5 mg in 0.9% sodium chloride 8 ml
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diamorphine 5 mg in 0.9% sodium chloride 8 ml with 1:200,000 adrenaline
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.375% bupivacaine 8 ml
Number of subjects: 51
Study: 7172717

Group type: EXPERIMENTAL
Intervention: Topical 2.5% phenylephrine hydrochloride
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 22
Study: 30652422

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 8-10 mg/kg of body weight per day
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 401
Study: 28248693

Group type: EXPERIMENTAL
Intervention: 1000 mg Calcium (CA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 51
Study: 27154593

Group type: EXPERIMENTAL
Intervention: Avoralstat 250 mg single dose
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Avoralstat 800 mg multiple doses (q8 h for up to 7 days)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Avoralstat 2400 mg/day multiple doses
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Avoralstat (doses ≥400 mg q8 h)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 24342144

Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 0
Study: 23147877

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 35
Study: 19686003

Group type: EXPERIMENTAL
Intervention: Self-regulatory processes during conflictual interactions
Number of subjects: 5

Group type: COMPARATOR
Intervention: High dispositional self-control
Number of subjects: 5

Group type: COMPARATOR
Intervention: Immediate response to partner provocations
Number of subjects: 5

Group type: COMPARATOR
Intervention: Depleted self-regulatory resources
Number of subjects: 5

Group type: COMPARATOR
Intervention: Bolstered self-regulatory resources via a 2-week training regimen
Number of subjects: 5
Study: 17890499

Group type: EXPERIMENTAL
Intervention: Change in perceived stress
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Heart rate reactivity
Number of subjects: 63
Study: 15375811

Group type: EXPERIMENTAL
Intervention: Targeted postoperative care based on preoperative risk assessment using the Risk Assessment and Prediction Tool (RAPT) in 50 patients (2001).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Targeted postoperative care in 2001.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Historical control group (50 patients treated in 2000).
Number of subjects: 100
Study: 16235068

Group type: EXPERIMENTAL
Intervention: Ultrasound-derived prediction equations for skeletal muscle mass
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ultrasound-derived prediction equations applied to validation group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 72
Study: 10393145

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention aimed at lowering dietary fat intake and increasing physical activity
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (weight-stable)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 236
Study: 8677539

Group type: EXPERIMENTAL
Intervention: New therapeutic developments for bladder cancer management in the elderly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSA‐based screening
Number of subjects: 0
Study: 1324534

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (3,000 anti-Xa units, one subcutaneous injection)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Low-dose heparin (5,000 U, subcutaneously three times a day)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Both groups (low molecular weight heparin and low-dose heparin)
Number of subjects: 653
Study: 6383491

Group type: EXPERIMENTAL
Intervention: Bestatin 10 mg orally three times daily for at least one year
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no further adjuvant treatment)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bestatin treatment
Number of subjects: 68
Study: 31660791

Group type: EXPERIMENTAL
Intervention: Type I interferon gene signature test-high patients
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Type I interferon gene signature test-low patients
Number of subjects: 681
Study: 30345906

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 902

Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel
Number of subjects: 902
Study: 27542350

Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring (FHRM) every 30 minutes
Number of subjects: 4612

Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring (FHRM) less than every hour or not at all
Number of subjects: 4612

Group type: EXPERIMENTAL
Intervention: Not using a partogram
Number of subjects: 4612
Study: 24135557

Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab (0.5 mg) injections
Number of subjects: 13
Study: 21986189

Group type: EXPERIMENTAL
Intervention: Iso GUM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reform GUM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Std GUM
Number of subjects: 30
Study: 19248192

Group type: EXPERIMENTAL
Intervention: Pantoprazole treatment for 3 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pantoprazole treatment for 6 months
Number of subjects: 58
Study: 17443469

Group type: EXPERIMENTAL
Intervention: High levels of macrophage migration inhibitory factor (MIF)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Circulating concentrations of MIF
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: MIF levels in meningococcal sepsis
Number of subjects: 145
Study: 15673630

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 850
Study: 12478843

Group type: EXPERIMENTAL
Intervention: Oral sildenafil (group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of prostaglandin E1 (PGE1) (group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intracavernosal injection of PGE1 (group B)
Number of subjects: 54
Study: 9803048

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for shortness of breath (SOB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for anxiety
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maximum inspiratory pressure (MIP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cardiac evaluation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Potentially correctable causes of dyspnea
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Assessment of respiratory muscle strength
Number of subjects: 100
Study: 7700741

Group type: EXPERIMENTAL
Intervention: RSVIG 750 mg/kg (high dose)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No RSVIG (control group)
Number of subjects: 162
Study: 31003670

Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 0
Study: 28550004

Group type: EXPERIMENTAL
Intervention: PhoS app
Number of subjects: 44

Group type: COMPARATOR
Intervention: Generalized relapse prevention training (Control)
Number of subjects: 44
Study: 25827133

Group type: EXPERIMENTAL
Intervention: Radiofrequency coblation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intramural bipolar cautery
Number of subjects: 41
Study: 23061828

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) 1200 mg/daily
Number of subjects: 1006
Study: 21813919

Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (3 g, 2 g L-carnitine/d; n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 15
Study: 19403652

Group type: EXPERIMENTAL
Intervention: Two-drug regimen (tenofovir disoproxil fumarate and efavirenz)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Three-drug regimen (tenofovir DF, lamivudine, and efavirenz)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Two-drug regimen (tenofovir DF and efavirenz)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 143
Study: 16314877

Group type: EXPERIMENTAL
Intervention: Peanut oil (30% of individual resting energy expenditure for 8 weeks)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Olive oil (30% of individual resting energy expenditure for 8 weeks)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Safflower oil (30% of individual resting energy expenditure for 8 weeks)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 129
Study: 15022504

Group type: EXPERIMENTAL
Intervention: Topical medications (antifungals or disinfectants)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 24
Study: 11286949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.8 g
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.8 g with Simvastatin 10 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Colesevelam 2.3 g
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Colesevelam 2.3 g with Simvastatin 20 mg
Number of subjects: 210
Study: 9250317

Group type: EXPERIMENTAL
Intervention: Riu stain
Number of subjects: 86

Group type: COMPARATOR
Intervention: Papanicolaou stain
Number of subjects: 86
Study: 8496756

Group type: EXPERIMENTAL
Intervention: Intermittent feedings
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous feedings
Number of subjects: 24
Study: 2446091

Group type: EXPERIMENTAL
Intervention: Aprotinin (high dosage, about 700 mg intravenously from the start of anaesthesia to the end of operation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aprotinin (high dosage)
Number of subjects: 22
Study: 29704972

Group type: EXPERIMENTAL
Intervention: Safety behavior after fear extinction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No safety behavior (control for A and B)
Number of subjects: 0
Study: 28317356

Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer
Number of subjects: 20
Study: 24448850

Group type: EXPERIMENTAL
Intervention: 'Eigenständig werden 5+6' school-based prevention programme
Number of subjects: 2513

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2513
Study: 22872770

Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg/d for 7 days
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 185
Study: 20484178

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 18560140

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT) with modified opposition restriction orthosis (MORO), 5 hours/day, 7 days/week for 8 weeks
Number of subjects: 21
Study: 15831644

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diastolic wall thickness (DWT) > 0.6 cm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of DSE improvement or DWT > 0.8 cm
Number of subjects: 24

Group type: COMPARATOR
Intervention: DSE alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DWT > 0.8 cm
Number of subjects: 24